CVS Health Past Earnings Performance
Past criteria checks 1/6
CVS Health's earnings have been declining at an average annual rate of -7.4%, while the Healthcare industry saw earnings growing at 2.1% annually. Revenues have been growing at an average rate of 8.2% per year. CVS Health's return on equity is 6.8%, and it has net margins of 1.4%.
Key information
-7.4%
Earnings growth rate
-6.6%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 8.2% |
Return on equity | 6.8% |
Net Margin | 1.4% |
Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
CVS Health: Why I'm Not Buying The Post-Earnings Share Buoyancy
May 01CVS Health (NYSE:CVS) Will Pay A Dividend Of $0.665
Apr 08CVS Health: I Don't Understand The Fuss, But The Worst Is Behind
Mar 30CVS Health (NYSE:CVS) Is Paying Out A Dividend Of $0.665
Mar 25Is CVS Health (NYSE:CVS) A Risky Investment?
Mar 07CVS Health: Incremental Improvement Best Hope For 2025 (Rating Downgrade)
Feb 26Market Might Still Lack Some Conviction On CVS Health Corporation (NYSE:CVS) Even After 25% Share Price Boost
Feb 17Earnings Beat: CVS Health Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 14CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold
Feb 13CVS Health Isn't Going To The Dogs
Jan 17CVS Health: An Attractive 5.8% Safe Yield For Now
Jan 10Market Cool On CVS Health Corporation's (NYSE:CVS) Earnings Pushing Shares 25% Lower
Dec 26CVS Health: When The Industry Is In Crisis, Don't Pick The Weaker Players
Dec 10There May Be Some Bright Spots In CVS Health's (NYSE:CVS) Earnings
Nov 19CVS Health: Cheap But No Signs Of Turnaround (Yet)
Nov 06CVS Health (NYSE:CVS) Has A Somewhat Strained Balance Sheet
Nov 03
Why CVS’s Valuation Signals Opportunity
Oct 30CVS Health has just faced a stock decline of about 10% after its preliminary Q3 earnings miss, which made the entire market aware. The decline is contributed largely to a $1.1 billion charge connectedCVS Health Stock Dip: Undervalued And Ready For A Turnaround
Oct 24CVS Health: Glenview's Activism Ramps Up Pressure On Management
Sep 30CVS Health: At Least There's A Valuable Lesson (Rating Downgrade)
Sep 10A Piece Of The Puzzle Missing From CVS Health Corporation's (NYSE:CVS) Share Price
Aug 08CVS Health Q2 Earnings: CEO's Swinging Axe May Have Ended The Bear Run
Aug 07Here's Why CVS Health (NYSE:CVS) Has A Meaningful Debt Burden
Jul 21CVS Health: A Better Investment Than Walgreens Boots Alliance
Jul 09Vltava Fund - CVS Health Corp.: Why We Sold CVS
Jul 03CVS Health: Mismanagement, Eroding Moat And Poor Momentum Make It A Sell
Jun 21The Correct Play On CVS Health
Jun 06CVS Health: Downside Movement Is Overdramatic
May 26CVS Health: Secure Dividend And Upside Potential Presents Compelling Opportunity
May 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CVS Health Corporation's (NYSE:CVS) CEO For Now
May 10Revenue & Expenses Breakdown
How CVS Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 25 | 376,741 | 5,280 | 41,689 | 0 |
31 Dec 24 | 370,656 | 4,614 | 41,229 | 0 |
30 Sep 24 | 367,246 | 5,016 | 41,052 | 0 |
30 Jun 24 | 361,855 | 7,190 | 40,354 | 0 |
31 Mar 24 | 359,662 | 7,321 | 39,798 | 0 |
31 Dec 23 | 356,623 | 8,344 | 39,205 | 0 |
30 Sep 23 | 346,601 | 8,632 | 38,836 | 0 |
30 Jun 23 | 338,072 | 2,965 | 38,629 | 0 |
31 Mar 23 | 329,915 | 4,093 | 38,135 | 0 |
31 Dec 22 | 321,629 | 4,311 | 37,922 | 0 |
30 Sep 22 | 314,343 | 3,283 | 37,970 | 0 |
30 Jun 22 | 306,933 | 8,287 | 37,549 | 0 |
31 Mar 22 | 298,770 | 8,041 | 37,252 | 0 |
31 Dec 21 | 290,912 | 8,001 | 36,764 | 0 |
30 Sep 21 | 283,981 | 7,586 | 36,046 | 0 |
30 Jun 21 | 277,285 | 7,212 | 35,270 | 0 |
31 Mar 21 | 270,115 | 7,404 | 34,972 | 0 |
31 Dec 20 | 267,908 | 7,188 | 34,585 | 0 |
30 Sep 20 | 265,285 | 7,951 | 33,907 | 0 |
30 Jun 20 | 262,980 | 8,257 | 33,881 | 0 |
31 Mar 20 | 260,961 | 7,217 | 33,226 | 0 |
31 Dec 19 | 255,765 | 6,629 | 32,699 | 0 |
30 Sep 19 | 243,331 | 4,464 | 30,515 | 0 |
30 Jun 19 | 226,053 | 4,324 | 27,032 | 0 |
31 Mar 19 | 209,623 | -174 | 23,924 | 0 |
31 Dec 18 | 193,919 | -597 | 20,827 | 0 |
30 Sep 18 | 188,055 | 3,098 | 33,284 | 0 |
30 Jun 18 | 186,967 | 2,989 | 28,379 | 0 |
31 Mar 18 | 185,944 | 6,645 | 18,987 | 0 |
31 Dec 17 | 184,765 | 6,606 | 18,737 | 0 |
30 Sep 17 | 182,351 | 5,029 | 4,607 | 0 |
30 Jun 17 | 180,785 | 5,281 | 9,215 | 0 |
31 Mar 17 | 178,825 | 5,108 | 18,362 | 0 |
31 Dec 16 | 177,526 | 5,291 | 18,284 | 0 |
30 Sep 16 | 172,701 | 5,084 | 18,102 | 0 |
30 Jun 16 | 166,729 | 4,781 | 17,677 | 0 |
31 Mar 16 | 160,173 | 5,126 | 17,234 | 0 |
31 Dec 15 | 153,290 | 5,202 | 16,833 | 0 |
30 Sep 15 | 149,199 | 5,027 | 16,673 | 0 |
30 Jun 15 | 145,577 | 4,741 | 16,712 | 0 |
31 Mar 15 | 143,010 | 4,713 | 16,688 | 0 |
31 Dec 14 | 139,367 | 4,626 | 16,543 | 0 |
30 Sep 14 | 135,142 | 4,576 | 16,378 | 0 |
30 Jun 14 | 132,053 | 4,887 | 16,100 | 0 |
Quality Earnings: CVS has high quality earnings.
Growing Profit Margin: CVS's current net profit margins (1.4%) are lower than last year (2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CVS's earnings have declined by 7.4% per year over the past 5 years.
Accelerating Growth: CVS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CVS had negative earnings growth (-27.9%) over the past year, making it difficult to compare to the Healthcare industry average (17.7%).
Return on Equity
High ROE: CVS's Return on Equity (6.8%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/04 07:43 |
End of Day Share Price | 2025/05/02 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CVS Health Corporation is covered by 60 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Harshit Gupta | Accountability Research Corporation |
Christopher Graja | Argus Research Company |
Samuel Hudson | Atlantic Equities LLP |